REVIEW ARTICLE

Genomics and Bioinformatics of Precision Pain Management: Molecular Basis for Targeted Interventions

Yohanna M Usman,[1*] Yusuf A Idris,[3] Tsoho F,[2] Wale R Hamza,[2] Christopher C,[4] Philip B Nyango,[1] Uchendu C,[3] Nanyak Z Galam[2]

Abstract

Genomics and bioinformatics have emerged as integral components of precision pain management, offering insights into the molecular basis of pain and personalized therapeutic interventions. This review explores the applications of genomics and bioinformatics in pain management, focusing on understanding pain genetics, molecular mechanisms, and clinical applications. This review was conducted to identify studies investigating the role of genomics and bioinformatics in pain management. PubMed, Web of Science, and relevant databases were searched for articles published in peer-reviewed journals. Keywords including "pain genetics," "bioinformatics," "precision medicine," and "pharmacogenomics" were used to identify relevant studies. Articles were screened based on their relevance to the topic, and relevant information was extracted for synthesis. The review highlights the contributions of genomics and bioinformatics to pain management, including the identification of candidate genes associated with pain susceptibility, genome-wide association studies elucidating genetic variants linked to pain phenotypes, and the development of predictive models for treatment response. Additionally, computational approaches enable the discovery of novel therapeutic targets and the design of more effective analgesic drugs. Genomics and bioinformatics hold promise for revolutionising pain management by enabling personalised interventions tailored to individual patients' genetic makeup and molecular profiles. Despite challenges such as ethical considerations and disparities in access to genomic technologies, collaborative efforts and technological advancements continue to drive progress in the field. Integrating genomic data and computational tools into clinical practice offers the potential to transform pain care, offering tailored interventions that alleviate suffering and improve the quality of life for patients worldwide.

Key Words: Bioinformatics, Genomics, Precision pain management, Pain genetics

Highland Med Res J 2024;24(2):01-07

https://dx.doi.org/10.4314/hmrj.v24i2.1

Introduction

Pain, a complex and subjective phenomenon, poses a significant challenge in healthcare due to its diverse etiology and variable response to treatments. While conventional pain management strategies often rely on a one-size-fits-all approach, the advent of precision medicine offers a promising avenue for personalised interventions tailored to individual patients.[1,2] Genomics and bioinformatics have emerged as indispensable tools in explaining the molecular basis of pain, creating the way for targeted interventions that addresses the underlying mechanisms of pain perception and response.[3]

Precision pain management encompasses a paradigm shift from the traditional trial-and-error approach to a more proactive and personalised strategy, aiming to optimise therapeutic outcomes while minimising adverse effects.[2] Precision pain management approach involves understanding that genetic variations and molecular pathways contribute to the variability in pain experience and treatment response among individuals.[4,5] Elucidating the genetic architecture and molecular mechanisms underlying pain, genomics and bioinformatics offer valuable insights into the development of more effective and personalised pain therapies.[6]

The genetic basis of pain perception has long been recognised, with studies implicating various genes and pathways in pain susceptibility and response to analgesics. Advances in genome-wide association studies (GWAS) have enabled the identification of genetic variants associated with different pain phenotypes, shedding light on the biological pathways involved in nociception, pain modulation, and analgesic metabolism.[7] Additionally, the advent of high-throughput sequencing technologies has facilitated the exploration of the entire genome and transcriptome, providing a comprehensive view of the genetic landscape of pain.[8]

Furthermore, molecular mechanisms underlying pain have been extensively studied, revealing intricate networks of neurotransmitters, receptors, ion channels, and inflammatory mediators involved in pain signalling and modulation.[9] Epigenetic modifications further contribute to the regulation of gene expression in chronic pain conditions, offering potential targets for

[1]Department of Human Anatomy, Faculty of Basic Medical Sciences, College of Health Sciences, University of Jos. [2]Department of Human Physiology, Faculty of Basic Medical Sciences, College of Health Sciences, University of Jos. [3]Department of Veterinary physiology& toxicology, Faculty of Veterinary Medicine, University of Jos. [4]Department of Human Physiology, Faculty of Basic Medical Sciences, College of Health Sciences, Federal University Wukari

All correspondences to:
Dr Yohanna M. Usman,
Email: usmany@unijos.edu.ng

intervention.[10] The integration of genomics and bioinformatics with molecular pain research holds the promise of identifying novel therapeutic targets and biomarkers for pain diagnosis, prognosis, and treatment response prediction.

This review is an overview of the current state of genomics and bioinformatics in precision pain management, highlighting key findings, challenges, and future directions in the field. By harmonising recent advances and emerging trends, the review underscores the transformative potential of genomic-driven approaches in unravelling the molecular basis of pain and guiding personalised interventions for improved patient outcomes.

Methodology for Data Extraction

This narrative review employed a structured approach to data extraction aimed at synthesising current knowledge on the genomic and bioinformatics landscape relevant to precision pain management. We conducted a comprehensive literature search using electronic databases including PubMed, Scopus, Web of Science, and Google Scholar to identify peer-reviewed articles, reviews, and relevant grey literature published between 2000 and 2025. Search terms included combinations of keywords such as "pain genetics", "bioinformatics", "precision medicine, "pharmacogenomics".

Articles were screened for relevance based on their titles and abstracts, with fulltexts retrieved for those meeting the inclusion criteria. Eligible studies were those that discussed the molecular and genetic basis of pain perception, chronic pain syndromes, pain-related gene variants, bioinformatics tools used in pain genomics, or clinical applications of precision interventions based on genomic profiling.

Data were extracted manually and independently by two reviewers to ensure accuracy and reduce bias. Extracted information included: (1) study objectives; (2) genomic markers or pathways identified; (3) bioinformatics platforms and analytical tools used; (4) type of pain condition studied; (5) clinical relevance or therapeutic implications; and (6) limitations or gaps highlighted. Discrepancies between reviewers were resolved through consensus or by involving a third reviewer.

To enhance narrative synthesis, data were thematically grouped under key areas such as nociceptor genomics, epigenetic regulation, gene-drug interactions, and integrative bioinformatics approaches. Special attention was given to translational aspects linking molecular findings with targeted interventions in clinical pain management. The final selection of studies aimed to provide a balanced and integrative perspective spanning basic research, computational analysis, and clinical application.

Pain Genetics

Pain perception is a complex trait influenced by a multitude of genetic factors.[11] Genetic studies have identified several key genes and pathways involved in pain processing, offering valuable insights into individual differences in pain sensitivity and susceptibility to chronic pain conditions. One of the fundamental aspects of pain genetics is the identification of candidate genes associated with pain phenotypes.[12] These genes encode proteins involved in neurotransmission, ion channel function, inflammatory response, and other molecular processes relevant to pain perception. For instance, variations in genes encoding opioid receptors (OPRM1), ion channels (SCN9A), and cytokines (TNF) have been linked to differences in pain sensitivity and susceptibility to chronic pain disorders.[13]

Genome-wide association studies (GWAS) have further expanded our understanding of the genetic basis of pain by enabling the discovery of genetic variants associated with specific pain traits.[14] GWAS analyses thousands to millions of genetic markers across the genome to identify variants that are significantly associated with a particular phenotype. Through GWAS, researchers have uncovered genetic loci associated with various pain conditions, including migraine, neuropathic pain, and osteoarthritis.[15] These findings not only provide insights into the underlying biology of pain but also offer potential targets for therapeutic intervention.

Polygenic risk scores (PRS) have emerged as a powerful tool for predicting individual susceptibility to pain and related disorders. PRS aggregate information from multiple genetic variants across the genome to estimate an individual's genetic risk for a particular phenotype.[16] By combining information from thousands of genetic variants, PRS can provide a more comprehensive assessment of genetic predisposition to pain, facilitating personalised risk stratification and intervention strategies.

Moreover, advances in functional genomics and systems biology have enhanced our understanding of the molecular pathways underlying pain. Integrative approaches combining genetic data with transcriptomic, epigenomic, and proteomic data have revealed detailed networks of genes and regulatory elements involved in pain processing.[17] These approaches not only identify potential drug targets but also elucidate the molecular mechanisms underlying individual differences in pain sensitivity and treatment response.

Molecular Mechanisms of Pain

Pain is mediated by delicate molecular pathways involving various neurotransmitters, receptors, ion channels, and inflammatory mediators.[9] The molecular mechanisms underlying pain perception and transmission are crucial for developing targeted interventions to alleviate pain and improve patient outcomes. Neurotransmitters play a central role in pain signalling within the nervous system. Glutamate, the primary excitatory neurotransmitter, activates N-methyl-D-aspatate (NMDA) and α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors, contributing to synaptic transmission and central sensitisation in pain pathways. In contrast, inhibitory neurotransmitters such as gamma-aminobutyric acid (GABA) and glycine modulate pain transmission by hyperpolarising neurons and reducing excitability.[18]

Ion channels also play a critical role in pain processing, particularly in the transmission of nociceptive signals. Voltage-gated sodium channels, including Nav1.7, Nav1.8, and Nav1.9, are essential for the generation and propagation of action potentials in nociceptive neurons.[19] Mutations in these channels have been associated with inherited pain disorders, highlighting their significance in pain perception. In addition to neurotransmitters and ion channels, inflammatory mediators contribute to the patho-physiology of pain, particularly in inflammatory and neuropathic pain conditions.[20] Pro-inflammatory cytokines such as interleukin-1 beta (IL-1β) and tumour necrosis factor-alpha (TNF-α) sensitize nociceptive neurons, leading to increased pain sensitivity and chronic pain states.[21] Moreover, the release of pro-inflammatory mediators can activate glial cells in the central nervous system, further amplifying pain signals and contributing to neuroinflammation.[22]

Epigenetic modifications, including DNA methylation, histone acetylation, and microRNA regulation, also play a crucial role in modulating gene expression in pain pathways. Chronic pain conditions are associated with alterations in epigenetic markers, leading to dysregulation of gene expression and persistent changes in neuronal function.[10] Overall, a comprehensive understanding of the molecular mechanisms of pain is essential for developing novel therapeutic strategies targeted at specific molecular sites within the pain pathway. By targeting key molecules involved in pain transmission and modulation, researchers can develop more effective and personalised treatments for pain management, ultimately improving the quality of life for individuals suffering from acute and chronic pain conditions.

Application of Genomics and Bioinformatics in Pain Management

Genomics and bioinformatics offer transformative opportunities in pain management by enabling a personalised approach to treatment and improving therapeutic outcomes.[23] By leveraging genetic and molecular data, clinicians can tailor interventions to individual patients, optimising efficacy and minimizing adverse effects. This section explores the diverse applications of genomics and bioinformatics in pain management, from pharmacogenomics to biomarker discovery and computational drug design.

Pharmacogenomics holds promise for optimising pain medication selection and dosing by considering individual genetic variations in drug metabolism and response.[6] Genetic polymorphisms in drug-metabolising enzymes, such as cytochrome P450 (CYP) enzymes, can influence the efficacy and toxicity of analgesic drugs.[24] For example, variants in CYP2D6 are associated with altered metabolism of opioids such as codeine and tramadol, impacting their analgesic efficacy and risk of adverse effects. Incorporating pharma-cogenomic information into clinical decision-making can guide the selection of the most appropriate analgesic therapy for each patient, enhancing treatment outcomes and minimising the risk of adverse reactions.

Biomarkers play a critical role in pain diagnosis, prognosis, and treatment response prediction.[25] Genomic biomarkers, such as genetic variants associated with pain susceptibility or treatment response, can provide valuable insights into individual differences in pain sensitivity and therapeutic outcomes.[26] Additionally, gene expression profiles obtained through transcriptomic analysis can identify molecular signatures associated with specific pain phenotypes or treatment responses.[27] Integrating genomic and transcriptomic data with clinical parameters enables the development of predictive models for patient stratification and personalised treatment selection.

Bioinformatics tools and computational approaches facilitate the discovery of novel therapeutic targets and the design of more effective analgesic drugs.[28] By analysing large-scale genomic and molecular datasets, researchers can identify key genes and pathways implicated in pain pathophysiology. Target identification and validation strategies, such as network analysis and pathway enrichment, prioritise candidate targets for drug development. Furthermore, computational methods, including molecular docking and virtual screening, expedite the identification of small molecules with therapeutic potential.[29] These in silico approaches enable the rational design of analgesic compounds with improved efficacy and selectivity,

accelerating the drug discovery process and reducing costs associated with traditional trial-and-error approaches.

Challenges and Future Directions

Despite the tremendous potential of genomics and bioinformatics in pain management, several challenges must be addressed to fully realise the benefits of personalised medicine in pain care. One of the foremost challenges is the ethical and privacy concerns associated with genomic data.[30] Genomic information is highly sensitive and raises ethical considerations regarding consent, data sharing, and potential misuse. Ensuring patient autonomy, confidentiality, and informed consent is paramount in genomic research and clinical practice.[31] Robust data security measures and transparent governance frameworks are essential to safeguard patient privacy and maintain public trust in genomic medicine.[32]

Interpreting genomic data in the context of pain management presents another challenge due to the complexity of genotype-phenotype relationships and the influence of environmental factors.[33] Integrating genomic information with clinical data, including patient-reported outcomes and environmental exposures, is critical for accurately predicting treatment response and optimising therapeutic interventions. Multidisciplinary collaboration between clinicians, geneticists, bioinformaticians, and other stakeholders is essential to navigate the complexity of genomic medicine and translate research findings into clinical practice.

Furthermore, disparities in access to genomic testing and personalised pain care pose significant challenges, particularly for underserved populations.[34] Socio-economic factors, geographic location, and healthcare infrastructure can limit access to genomic technologies and specialised pain management services, exacerbating health disparities.[35] Addressing these disparities requires concerted efforts to promote equitable access to genomic testing, expand education and training in genomic medicine, and enhance healthcare infrastructure in underserved communities.[36]

Looking ahead, several future directions hold promise for advancing genomics and bioinformatics in pain management. Integrating artificial intelligence (AI) and machine learning algorithms into genomic analysis enables the identification of complex genotype-phenotype associations and the development of predictive models for personalised pain care.[37] AI-driven approaches can analyse vast genomic datasets, uncover hidden patterns, and generate actionable insights to guide clinical decision-making.[38]

Moreover, the emergence of precision health initiatives and large-scale genomic cohorts offers unprecedented opportunities for collaborative research and data sharing in pain genomics. Collaborative consortia and data-sharing platforms facilitate the aggregation of genomic and clinical data from diverse populations, enabling robust analyses and discovery of novel pain-related genes and pathways. By fostering interdisciplinary collaboration and data sharing, these initiatives accelerate the translation of genomic discoveries into clinical practice and improve patient outcomes in pain management.

Addressing the ethical, technical, and accessibility challenges while embracing innovative technologies and collaborative approaches is essential for realising the full potential of genomics and bioinformatics in personalised pain management. By overcoming these challenges and seizing future opportunities, we can advance towards a future where genomic-driven approaches transform pain care, offering tailored interventions that alleviate suffering and improve the lives of patients worldwide.[39]

The application of genomics and bioinformatics in pain management holds immense potential for advancing personalised medicine and improving patient care. By integrating genetic and molecular data into clinical practice, clinicians can tailor interventions to individual patients, optimising treatment outcomes and enhancing the quality of life for individuals suffering from acute and chronic pain conditions.

Case Studies and Clinical Applications

Case studies and clinical applications provide tangible examples of how genomics and bioinformatics are being translated into real-world practice, revolutionising pain management and improving patient outcomes. One compelling example is the use of pharmacogenomic testing to guide opioid therapy in chronic pain patients.[40]

By analysing genetic variants in drug-metabolising enzymes and opioid receptors, clinicians can identify individuals at increased risk of adverse drug reactions or poor treatment response. For instance, a patient with a genetic predisposition for ultra-rapid metabolism of opioids may require higher doses for adequate pain relief, while another patient with reduced opioid receptor sensitivity may benefit from alternative analgesic strategies.[41] Pharmacogenomic-guided opioid therapy not only enhances pain control but also reduces the risk of opioid-related side effects, including respiratory depression and addiction.[42]

Another notable clinical application is the development of genomic biomarkers for pain diagnosis and prognosis.[29] For example, genetic variants associated with an increased risk of developing chronic pain following surgery or trauma can help identify patients at heightened risk, allowing for early intervention and preventive measures.[43] Similarly, gene expression

signatures obtained from peripheral blood or tissue samples can serve as prognostic markers for treatment response and disease progression in chronic pain conditions. Integrating genomic biomarkers into clinical practice enables more precise risk stratification and personalised treatment selection, leading to improved patient outcomes and healthcare resource utilisation.[44]

Furthermore, computational approaches and machine learning algorithms are increasingly being used to analyse genomic and clinical data and generate predictive models for pain management.[45] For instance, machine learning algorithms trained on large-scale genomic datasets can predict individual pain sensitivity or treatment response based on genetic profiles, demographic factors, and clinical characteristics. These predictive models empower clinicians to tailor interventions to individual patients, optimising therapeutic outcomes and minimising trial-and-error in pain management.

Overall, case studies and clinical applications highlight the transformative impact of genomics and bioinformatics on pain care. By harnessing the power of genomic data and computational tools, clinicians can deliver personalised interventions that address the underlying molecular mechanisms of pain and improve the lives of patients suffering from acute and chronic pain conditions. As genomic medicine continues to evolve, it holds the promise of revolutionising pain management and paving the way for precision medicine approaches tailored to the individual needs of each patient.[46]

Conclusion

Genomics and bioinformatics have emerged as powerful tools in precision pain management, offering unprecedented insights into the molecular basis of pain and personalised therapeutic interventions.[47] Through the integration of genetic and molecular data with clinical practice, clinicians can tailor treatments to individual patients, optimising efficacy and minimising adverse effects. The understanding of pain genetics has expanded rapidly, with genome-wide association studies identifying genetic variants associated with pain susceptibility and treatment response. Additionally, advancements in molecular biology have elucidated intricate pathways involved in pain perception, offering novel targets for therapeutic intervention.

Despite the progress made, challenges remain in translating genomic discoveries into clinical practice, including ethical considerations, data interpretation, and disparities in access to genomic technologies. Addressing these challenges require collaborative efforts across disciplines and stakeholders to ensure equitable access to personalised pain care and safeguard patient privacy and autonomy.

Looking ahead, the future of genomics and bioinformatics in pain management holds great promise. Advances in artificial intelligence and machine learning are poised to revolutionise genomic analysis, enabling the development of predictive models for pain diagnosis, prognosis, and treatment response. Furthermore, collaborative initiatives and data-sharing platforms are expanding our understanding of pain genetics and facilitating the translation of genomic discoveries into clinical practice.

Genomics and bioinformatics are transforming pain management by enabling personalised interventions tailored to individual patients' genetic makeup and molecular profiles. By harnessing the power of genomic data and computational tools, we can revolutionise pain care, offering targeted therapies that alleviate suffering and improve the quality of life for millions of patients worldwide. As we continue to advance in genomic medicine, the vision of precision pain management becomes increasingly attainable, promising a future where every patient receives personalised, effective, and compassionate care for their pain.

References

1. Edwards RR, Schreiber KL, Dworkin RH. Optimizing and accelerating the development of precision pain treatments for chronic pain: IMMPACT review and recommendations. J Pain. 2023; 24(2): 204 - 225.
2. Chadwick A, Frazier A, Khan TW, Young E. Understanding the psychological, physiological, and genetic factors affecting precision pain medicine: a narrative review. J Pain Res. 2021; 14: 3145-3161.
3. Sunil KG, Joshi A, Kaushik V. Bioinformatics in Personalized Medicine. In: Singh V, Kumar A eds. Advances in Bioinformatics. Springer, Singapore, 2021; 303 – 315.
4. Shi Q, Cleeland CS, Klepstad P, Miaskowski C, Pedersen NL. Biological pathways and genetic variables involved in pain. Qual Life Res. 2010;19: 1407-1417.
5. Lu L. The impact of genetic variation on sensitivity to opioid analgesics in patients with postoperative pain: a systematic review and meta-analysis. Pain Phys. 2015; 18:131-152.
6. Kaye AD, Garcia AJ, Hall OM. Update on the pharmacogenomics of pain management. Pharmacogenomics Pers Med. 2019; 12: 125-143.
7. Peters MJ, Broer L, Willemen HL. Genome-wide association study meta-analysis of chronic widespread pain: evidence for involvement of the 5p15. 2 region. Ann Rheum Dis. 2013; 72(3): 427 - 436.
8. Kringel D, Kaunisto MA, Lippmann C, Kalso E,

Lötsch J. Development of an AmpliSeqTM panel for next-generation sequencing of a set of genetic predictors of persisting pain. Front Pharmacol. 2018; 9: 400471. doi: 10.3389/fphar.2018.01008. PMID: 30283335; PMCID: PMC6156278. Accessed 17th June, 2024.
9. Yam MF, Loh YC, Tan CS, Khadijah AS, Abdul MN, Basir R. General pathways of pain sensation and the major neurotransmitters involved in pain regulation. Int J Mol Sci. 2018; 19(8): 2164. doi: 10.3390/ijms19082164. PMID: 30042373; PMCID: PMC6121522. Accessed 30th May, 2024.
10. Géranton SM, Tochiki KK. Regulation of gene expression and pain states by epigenetic mechanisms. Prog Mol Biol Transl Sci. 2015; 131:147-183.
11. James S. Human pain and genetics: some basics. Br J Pain. 2013; 7(4): 171-178.
12. Ultsch A, Kringel D, Kalso E, Mogil JS, Lötsch J. A data science approach to candidate gene selection of pain regarded as a process of learning and neural plasticity. Pain. 2016; 157(12): 2747 - 2757.
13. Cregg R, Russo G, Gubbay A, Branford R, Sato H. Pharmacogenetics of analgesic drugs. Br J Pain. 2013; 7(4): 189 - 208.
14. Li S, Brimmers A, van Boekel RL, Vissers KC, Coenen MJ. A systematic review of genome-wide association studies for pain, nociception, neuropathy, and pain treatment responses. Pain. 2023; 164(9): 1891 - 1911.
15. Nishizawa D, Iseki M, Arita H. Genome-wide association study identifies candidate loci associated with chronic pain and postherpetic neuralgia. Mol Pain. 2021; 17: 1744806921999924. doi:10.1177/1744806921999924 Accessed 17th June, 2024.
16. McIntosh AM, Hall LS, Zeng Y. Genetic and environmental risk for chronic pain and the contribution of risk variants for major depressive disorder: a family-based mixed-model analysis. PLoS Med. 2016; 13(8): e1002090. doi: 10.1371/journal.pmed.1002090. PMID: 27529168; PMCID: PMC4987025. Accessed 20th May, 2024.
17. Steinberg J, Ritchie GR, Roumeliotis TI. Integrative epigenomics, transcriptomics and proteomics of patient chondrocytes reveal genes and pathways involved in osteoarthritis. Sci Rep. 2017; 7(1): 8935. doi: 10.1038/s41598-017-09335-6. PMID: 28827734; PMCID: PMC5566454. Accessed 20th May, 2024.
18. Willis Jr WD. Role of neurotransmitters in sensitization of pain responses. Ann N Y Acad Sci. 2001; 933(1):142-156.
19. Hameed S. Nav1. 7 and Nav1. 8: Role in the pathophysiology of pain. Mol Pain. 2019; 15:17 44806919858801. doi: 10.1177/1744806919858801. PMID: 31172839; PMCID: PMC658 9956. Accessed 17th May, 2024.
20. Ronchetti S, Migliorati G, Delfino DV. Association of inflammatory mediators with pain perception. Biomed Pharmacother. 2017; 96:1445-1452.
21. Fang XX, Zhai MN, Zhu M. Inflammation in pathogenesis of chronic pain: Foe and friend. Mol Pain. 2023; 19: 17448069231178176. doi: 10.1177/17448069231178176. PMID: 37220667; PMCID: PMC10214073. Accessed 29th June, 2024.
22. Donnelly CR, Andriessen AS, Chen G. Central nervous system targets: glial cell mechanisms in chronic pain. Neurotherapeutics. 2020; 17(3): 846 - 860.
23. Lippmann C, Kringel D, Ultsch A, Loetsch J. Computational functional genomics-based approaches in analgesic drug discovery and repurposing. Pharmacogenomics. 2018; 19(9): 783-797.
24. Zhao M, Ma J, Li M. Cytochrome P450 enzymes and drug metabolism in humans. Int J Mol Sci. 2021; 22(23): 12808. doi: 10.3390/ijms222312808. PMID: 34884615; PMCID: PMC8657965. Accessed 21st April, 2024.
25. Eldabe S, Obara I, Panwar C, Caraway D. Biomarkers for chronic pain: significance and summary of recent advances. Pain Res Manag. 2022; 2022: 1940906. doi: 10.1155/2022/1940906. PMID: 36385904; PMCID: PMC9663208. Accessed 21st April, 2024.
26. Niculescu AB, Le-Niculescu H, Levey DF. Towards precision medicine for pain: diagnostic biomarkers and repurposed drugs. Mol Psychiatry. 2019; 24(4): 501 - 522.
27. Islam B, Stephenson J, Young B. The identification of blood biomarkers of chronic neuropathic pain by comparative transcriptomics. Neuro Mol Med. 2022; 24(3): 320 - 338.
28. Sun Y, Yang J. A bioinformatics investigation into the pharmacological mechanisms of the effect of Fufang Danshen on pain based on methodologies of network pharmacology. Sci Rep. 2019; 9(1): 5913. doi: 10.1038/s41598-019-40694-4. PMID: 30976033; PMCID: PMC6459854. Accessed 20th May, 2024.
29. Lin X, Li X, Lin X. A review on applications of computational methods in drug screening and design. Molecules. 2020; 25(6): 1375. doi: 10.3390/molecules25061375. PMID: 32197324; PMCID: PMC7144386. Accessed 20th May, 2024.
30. Takashima K, Maru Y, Mori S, Mano H, Noda T, Muto K. Ethical concerns on sharing genomic data including patients' family members. BMC Med Ethics. 2018; 19: 1 - 6.
31. Martinez-Martin N, Magnus D. Privacy and ethical

challenges in next-generation sequencing. Expert Rev Precis Med Drug Dev. 2019; 4(2): 95-104.
32. Mohammed YA, Chen YP. Ensuring privacy and security of genomic data and functionalities. Brief Bioinform. 2020; 21(2): 511 - 526.
33. Tsepilov YA, Freidin MB, Shadrina AS, et al. Analysis of genetically independent phenotypes identifies shared genetic factors associated with chronic musculoskeletal pain conditions. Commun Biol. 2020; 3(1):329. doi: 10.1038/s42003-020-1051-9. PMID: 32587327; PMCID: PMC7316754. Accessed 20th May, 2024.
34. Kessler MD, Yerges-Armstrong L, Taub MA. Challenges and disparities in the application of personalized genomic medicine to populations with African ancestry. Nat Commun. 2016; 7(1): 12521. doi: 10.1038/ncomms12521. PMID: 27725664; PMCID: PMC5062569. Accessed 20th May, 2024.
35. Chediak L, Bedlington N, Gadson A. Unlocking sociocultural and community factors for the global adoption of genomic medicine. Orphanet J Rare Dis. 2022; 17(1): 191. doi: 10.1186/s13023-022-02328-3. PMID: 35549752; PMCID: PMC9097338. Accessed 17th May, 2024.
36. Jooma S, Hahn MJ, Hindorff LA, Bonham VL. Defining and achieving health equity in genomic medicine. Ethn Dis. 2019; 29(Suppl 1): 173 - 178.
37. Quazi S. Artificial intelligence and machine learning in precision and genomic medicine. Med Oncol. 2022; 39(8): 120. doi: 10.1007/s12032-022-01711-1. PMID: 35704152; PMCID: PMC9198206. Accessed 24th April, 2024.
38. Rezaei M, Rahmani E, Khouzani SJ. Role of artificial intelligence in the diagnosis and treatment of diseases. Kindle. 2023; 3(1): 1 - 60.
39. Kim H, Dionne RA. Individualized pain medicine. Drug Discov Today Ther Strateg. 2009; 6(3): 83 - 87.
40. Yamamoto PA, Conchon-Costa AC, Lauretti GR, De-Moraes NV. Pharmacogenomics in chronic pain therapy: from disease to treatment and challenges for clinical practice. Pharmacogenomics. 2019; 20(13): 971 - 982.
41. Bugada D, Lorini LF, Fumagalli R, Allegri M. Genetics and opioids: towards more appropriate prescription in cancer pain. Cancers (Basel). 2020; 12(7): 1951. doi: 10.3390/cancers12071951. PMID: 32708424; PMCID: PMC7409018. Accessed 24th April, 2024.
42. Wong AK, Somogyi AA, Rubio J, Philip J. The role of pharmacogenomics in opioid prescribing. Curr Treat Options Oncol. 2022; 23(10): 1353 - 1369.
43. Li S, van Boekel RL, van den Heuvel SA, Coenen MJ, Vissers KC. Pain predict genetics: protocol for a prospective observational study of clinical and genetic factors to predict the development of postoperative pain. BMJ Open. 2022; 12(11): e066134. doi: 10.1136/bmjopen-2022-066134. PMID: 36446453; PMCID: PMC9710368. Accessed 24th April, 2024.
44. Restrepo JC, Dueñas D, Corredor Z, Liscano Y. Advances in genomic data and biomarkers: revolutionizing NSCLC diagnosis and treatment. Cancers (Basel). 2023; 15(13): 3474. doi: 10.3390/cancers15133474. PMID: 37444584; PMCID: PMC10340640. Accessed 17th May, 2024.
45. Lötsch J, Ultsch A, Mayer B, Kringel D. Artificial intelligence and machine learning in pain research: a data scientometric analysis. Pain Rep. 2022; 7(6): e1044. doi: 10.1097/PR9.0000000000001044. PMID: 36348668; PMCID: PMC9635040. Accessed 17th April, 2024.
46. Doshi T, Arissa T. Pain Genomics: Defining the Vulnerable Patient. In: Paul JC, Rollin MG, Joanna GK, Kayode AW eds. Pain Management in Vulnerable Populations (New York, 2024; online edn, Oxford Academic, 1 June 2024): 36 – 58. https://doi.org/10.1093/med/9780197649176.003.0003, Accessed 29 June 2024.
47. Gazerani P, Vinterhøj HS. 'Omics': an emerging field in pain research and management. Future Neurol. 2016; 11(4): 255 - 265.